The Diagnostic Biomarkers and Technologies Branch (DBT) supports research that leads to the discovery of new cancer markers by correlating the molecular characteristics of tumors with important clinical parameters of cancer patients. Approaches may include the use of current genomic, pathologic and proteomic technologies including but not limited to comparative genomic hybridization (CGH), single nucleotide polymorphism (SNP) analysis, epigenetic analysis, cDNA arrays, mRNA splicing analysis, DNA mutation analysis, miRNA expression analysis, immunohistochemical analysis (IHC), in situ hybridization, protein arrays studies and MALDI-TOF analysis. The studies may include the use of human tissue samples, tissue microarrays, human cancer cell lines, human tumor xenografts and animal models. Studies are supported through investigator initiated R01 applications. Early studies in marker discovery and validation in human cancer utilizing these approaches can be supported by an R21 mechanism through PA-06-299 (http://grants.nih.gov/grants/guide/pa-files/PA-06-299.html).
Experimental areas of interest include, but are not limited to the following:
For additional information on cancer marker development and validation see Diagnostic Evaluation Branch (DEB)